Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Summary

This phase I trial studies how well CBX-12 works in treating patients with solid tumors that have spread from where they first started (primary site) to started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or other places in the body (metastatic). CBX-12 works by binding to a protein called TOP1 that is present inside the cells. This allows CBX-12 to kill the cancer cells by damaging their DNA, resulting in cancer cell death. This trial is being done to find out if this approach is better or worse than the usual approach for advanced cancers.

Timeline

Start

2024-06-12

Primary completion

2026-10-15

Completion

2026-10-15

Drugs

Indications